MIROCALS consortium is formed by 12 organisations in the EU to conduct a phase II Proof of Concept / Proof of Mechanism Clinical Trial aiming to test the interleukin-2 (IL-2) as treatment for amyotrophic lateral sclerosis (ALS).

The science of the project is coordinated by Dr Gilbert Bensimon of the University Hospital of Nimes (France) which is the trial sponsor, and Professor P. Nigel Leigh of the Brighton and Sussex Medical School (UK).

Around them, the MIROCALS consortium brings together a strong partnership of: leading scientists and clinicians from six European laboratories in France, Italy, Sweden and UK; two clinical research organisations for professional biobanking and trial regulatory-compliant monitoring; the MND Association one of the most active patients’ associations in the field of neurodegeneration worldwide and an EU project management company.

MIROCALS is a 4-year collaborative research project started in September 2015 and supported by the European Union’s Horizon 2020 research and innovation Programme.


Logo CHU Inserm Transfert Logo

University Hospital of Nimes
Nîmes, France

Inserm Transfert
Paris, France

ICON logo jpg original Généthon EN Q

ICON plc

Evry, France

HumanitasRH 1498139 ny logo en high

Humanitas Research Hospital
Milan, Italy

University of Gothenburg

US small pos k tuoslogo key

University of Sussex

University of Sheffield

kingslondon queen mary

King's College London
London, UK

Queen Mary University
London, UK


Motor Neurone Disease Association

WGK Consultancy Ltd


MIROCALS 2nd General meeting in Milan, June 7-8th 2018

The next consortium meeting of MIROCALS will be held on June 7th and 8th 2018 in Milan to present the progress made since thebeginning of the project.

MIROCALS 1st General Assembly meeting in Brighton, June 9 & 10th 2016

This meeting gathered all MIROCALS partners for presenting the progress made since the launch of the project a year ago as well as the next achievements for the coming year. 

First participant recruited to MIROCALS trial

The MIROCALS consortium is delighted to announce that the first participant has been recruited to the MIROCALS trial, at Hospices Civils de Lyon, France.

Read more.


This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 633413.